• Skip to primary navigation
  • Skip to main content
Drug Hunter - discover together

Drug Hunter

Sign Up for our newsletter
  • Molecules
  • Resources
  • Articles
  • Events
  • Career Listings
  • Find Partners
    • Drug Discovery CROs
    • Drug Development CDMOs
    • Drug Discovery Products
    • Drug Discovery Equipment
    • Drug Discovery Companies
    • Drug Discovery Investors
  • Premium
  • About Us
  • Advisory Board
  • Our Reviewers
  • Our Team
  • Sponsors
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Advertise
  • Blog
  • LinkedIn
  • twitter

© Rosalind Scientific LLC 2018-2022

  • Molecules
  • Resources
  • Articles
  • Events
  • Career Listings
  • Find Partners
    • Drug Discovery CROs
    • Drug Development CDMOs
    • Drug Discovery Products
    • Drug Discovery Equipment
    • Drug Discovery Companies
    • Drug Discovery Investors
  • Premium
Subscribe Log in
  • LinkedIn
  • twitter

New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.

Consent(Required)
(Required)
Subscribe Log in

immunotherapy

  • Cover image of Drug Hunter article "The Global Cancer Immunotherapy Pipeline"

    The Global Cancer Immunotherapy Pipeline

    The global cancer immunotherapy pipeline continues to explode with nearly double the number of active targets in 2019 vs. only two years ago, comprising 3,876(!!) active drugs, with a subset undergoing >5000 active clinical trials. In 2016, I listened to Dan Chen, former Global Head of Cancer Immunotherapy Development at Genentech, comment on the challenge…

  • Cover image of Drug Hunter article "That Jimmy Carter Drug"

    That Jimmy Carter Drug

    Checkpoint inhibitors like pembrolizumab (Keytruda) have revolutionized treatment for many late-stage cancer patients, including Jimmy Carter. Recently, Keytruda stunned the world again with efficacy in metastatic non-small cell lung cancer, the leading cancer killer. Here’s a summary of its recent successes and the surprising path Keytruda took through two acquisitions and the Merck “out-license” list.…

Sign Up for our newsletter
  • Molecules
  • Resources
  • Articles
  • Events
  • Career Listings
  • Find Partners
    • Drug Discovery CROs
    • Drug Development CDMOs
    • Drug Discovery Products
    • Drug Discovery Equipment
    • Drug Discovery Companies
    • Drug Discovery Investors
  • Premium
  • About Us
  • Advisory Board
  • Our Reviewers
  • Our Team
  • Sponsors
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Advertise
  • Blog
  • LinkedIn
  • twitter

© Rosalind Scientific LLC 2018-2022